Navigation Links
Delcath Announces Fiscal 2011 Third Quarter Results and Recent Developments
Date:11/7/2011

amp;A) expenses were $5.7 million for the third quarter of 2011, compared to $3.2 million for the same period in the prior year.
The increase in G&A was primarily due to an expansion in staff as the Company continued its progress in transitioning from a development stage company to a commercial enterprise and preparations for commercialization in Europe. Research and development (R&D) expenses were $6.4 million for the third quarter of 2011, compared to $4.3 million for the same period in the prior year.
The increase in R&D expenses was primarily due to our expanded research and development activities and regulatory expenses related to the preparation of our NDA submission for the FDA.

For the nine months ended September 30, 2011, the Company's operating loss was $30.5 million, which included approximately $3.4 million in non-cash stock-based compensation expense. This compares to an operating loss for the nine months ended September 30, 2010 of $21.2 million, which included approximately $3.9 million in non-cash stock-based compensation expense. G&A expenses were $15.1 million for the nine months ended September 30, 2011, compared to $9.4 million for the nine months ended September 30, 2010. The increase in G&A was primarily due to an expansion in staff as the Company continued its progress in transitioning from a development stage company to a commercial enterprise and preparations for commercialization in Europe. R&D expenses were $15.3 million for the nine months ended September 30, 2011, compared to $11.8 million during the first nine months of 2010. During 2010, the Company was incurring expenses related to wrapping up its Phase III clinical trial. The reduction in trial related expenses during 2011 was more than offset by an increase in expenses related to our expanded research and development activities and regulatory expenses related to our submission to the FDA.

At September 30, 2011, cash, cash equivalents and c
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Delcath Systems to Report Third Quarter Progress and Conduct Conference Call
2. FDA Schedules Delcath Pre-New Drug Application Meeting Date
3. Delcath Announces Completion of Regulatory Notification Process in New Zealand
4. Delcath Announces Updated Efficacy Results From Phase 3 Trial of Chemosaturation for Melanoma Metastases in the Liver Presented at European Multidisciplinary Cancer Congress
5. Delcath to Present at the JMP Securities Healthcare Conference on September 28, 2011
6. Delcath Systems, Inc. Hosts Symposium on Chemosaturation at CIRSE Annual Meeting
7. Delcath Announces Top-Line Results From Metastatic Colorectal Cohort in Phase II Trial of Chemosaturation System
8. Delcath Announces Encouraging Top-Line Results From Hepatobiliary Cohort in Phase II Trial of Chemosaturation System
9. Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011
10. Delcath Systems to Report Second Quarter Progress Update and Conduct Conference Call
11. Delcath Systems, Inc. Announces the Completion of Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Research and Markets  has announced the addition of ... & by Lead Type - Global Forecast to 2020" ... http://photos.prnewswire.com/prnh/20130307/600769 The global diagnostic electrocardiograph ... holter monitor, resting, and stress type diagnostic ECG devices. ... 2013 and is poised to grow at a CAGR ...
(Date:7/23/2014)... , July 23, 2014 On Tuesday, ... ("Plaintiff") filed suit in the 116 th ... , against RegenLab USA, LLC ... Prospective Business Relationships through false and misleading ... Business Disparagement through libel, disparagement, defamation, ...
(Date:7/23/2014)... , July 23, 2014 Research ... the "Global Electrophysiology Ablation Catheters Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Catheter ablation ... or destroy faulty electrical pathways from sections of ... known as cardiac arrhythmias). Cardiac arrhythmias can be ...
Breaking Medicine Technology:Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 2Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 3Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 2Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 3
... June 16, 2011 Atrium Medical Corporation today announced that ... Award , presented by the Premier healthcare alliance . ... and Atrium is one of 39 contracted suppliers to receive ... of Premier agreements and their drive toward the mutual goal ...
... June 16, 2011 Rigel Pharmaceuticals, Inc. (Nasdaq: ... president and chief operating officer, is scheduled to present a ... in Boston, MA on Thursday, June 23rd at 9:30 a.m. ... of the company presentation or the subsequent archived recording, log ...
Cached Medicine Technology:Atrium Honored by the Premier Healthcare Alliance for Operational Excellence 2Atrium Honored by the Premier Healthcare Alliance for Operational Excellence 3
(Date:7/23/2014)... DC (PRWEB) July 23, 2014 ... for ATA 2015, ATA’s twentieth annual meeting and ... The meeting, expected to attract over 5,000 attendees ... will take place May 3-5, 2015, in Los ... most renowned healthcare technology professionals from researchers, clinicians, ...
(Date:7/23/2014)... ( FXS ) is a genetic disorder that causes ... autistic spectrum, as well as cognitive deficits. It is ... the most common cause of autism. , Now biomedical ... a study that sheds light on the ... (July 23) in the Journal of Neuroscience , ...
(Date:7/23/2014)... Olympic gold medal-winning speed skater Chad Hedrick ... July 18. Hedrick visited Roanoke as the special guest ... Olympic-style event celebrating its 25th Anniversary in 2014. Foot ... sponsor of the Commonwealth Games, which like Foot Levelers ... all activity levels. , Hedrick, a native of Houston, ...
(Date:7/23/2014)... Amy Norton HealthDay ... The timing of a girl,s first menstrual period may be ... new study suggests. Researchers have identified over 100 ... menarche -- a woman,s first menstrual period. The researchers hope ... number of diseases ranging from type 2 diabetes to breast ...
(Date:7/23/2014)... 2014 Texas Physical Therapy Specialists (TexPTS) ... their Westlake, Westgate, Liberty Hill, Parmer, Balcones, and Georgetown ... of Orthopaedic Certified Specialist (OCS) or ... PT, DPT, OCS, Tony Lauretta, PT, DPT, OCS, Jason ... Joseph Leech, PT, DPT, OCS, and Mary Grimberg, PT, ...
Breaking Medicine News(10 mins):Health News:ATA Seeks Speakers to Present at the World’s Largest Telemedicine, mHealth and Telehealth Conference 2Health News:Study links enzyme to autistic behaviors 2Health News:Study links enzyme to autistic behaviors 3Health News:US Olympian Chad Hedrick Visits Foot Levelers 2Health News:Gene Study Gives New Insight Into Puberty in Girls 2Health News:Gene Study Gives New Insight Into Puberty in Girls 3Health News:Texas Physical Therapy Specialists Congratulates New Board Certified Specialists 2Health News:Texas Physical Therapy Specialists Congratulates New Board Certified Specialists 3
... the millions of Americans whose vision is slowly ebbing due ... cell may be riding to the rescue. ,In ... fetal stem cells have been shown to protect the vision ... of diseases that afflict humans. The new study appears today ...
... Diabetes and high blood pressure, two conditions rooted in ... than race alone in determining// who is mostly likely ... from cardiologists at Johns Hopkins. Each year, nearly 300,000 ... ,Experts say that racial disparities have long been known ...
... be a decade or more before science is available to ... way the agency approves knockoffs of traditional drugs. ... benefit companies such as Amgen Inc. and Genentech Inc, which ... products, some of the most complex and expensive on the ...
... LEXINGTON, Ky. − When studying a new blood thinner, one ... a slight increase in minor bleeding—nose bleeds and bruising,// an ... the leading cause of heart attack and stroke. While potentially ... bleeding in some patients, requiring frequent monitoring of blood levels. ...
... ancient parasitic disease causing tennis-ball-size ulcers so painful that ... in less than two years// become the second illness ... water treatment and other preventive methods, the United Nations ... the culmination of years of effort by local and ...
... Hewitt, the health secretary said that computer based therapy ... and anxiety//. This will be available to all patients ... Fear fighter and Beating the blues have been designed ... health experts have warned that computer aided programs may ...
Cached Medicine News:Health News:Stem Cell Therapy Shows Promise for Rescuing Deteriorating Vision 2Health News:Stem Cell Therapy Shows Promise for Rescuing Deteriorating Vision 3Health News:Who Gets Heart Failure? Race Takes Back Seat to Diabetes and High Blood Pressure 2Health News:Who Gets Heart Failure? Race Takes Back Seat to Diabetes and High Blood Pressure 3Health News:FDA Cites Challenges of Generic Biotech 2Health News:New Blood Thinner May Work Without Bleeding Risk 2Health News:Ancient Worm Disease Could Be Eradicated Within Two Years, UN Agency Reports 2Health News:Computer Based Therapy For Depression 2
Monitorr ICP external CSF drainage system with self-contained ICP setting....
... Sophysa external neurological drainage system combines ... all the essential functions for CSF ... technological solutions contribute to make this ... is available as a single item ...
... for neuro and skull base surgery. ... craniofacial surgery, pediatric neurosurgery, bony defects ... skull base regions, neuro trauma. Dedicated ... implants in one compact kit. MRI ...
14 cm - 5 1/2, 6.0 mm , for drill handles and hand drills....
Medicine Products: